5-Amino-1MQ

5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme associated with fat-cell metabolism and cellular NAD+ availability. It is investigated in metabolic enzyme research, mainly in preclinical settings. It is not a peptide in the strict sense, but is commonly grouped with research compounds of interest in metabolic and performance-related studies. CoreX supplies it for laboratory research use only.

Research investigates 5-Amino-1MQ for its inhibition of NNMT, an enzyme highly expressed in adipose tissue and linked to metabolic rate. Blocking NNMT is studied for downstream effects on adipocyte energy expenditure. Researchers have also explored knock-on effects on the NAD+ salvage pathway, which recycles NAD+ within the cell. These mechanisms are proposed from laboratory and animal work, and their relevance in humans has not been established.

Preclinical studies have examined NNMT inhibition in models of obesity-related metabolic dysfunction, reporting effects on metabolic measures in animals. Other animal work has studied NNMT inhibition in experimental peripheral artery disease, with reported improvements in limb function. Broader NNMT research has also looked at the enzyme's role in fatty liver development and in tumour biology. These findings are early and come from animal and cell models rather than human trials.

Human safety data for 5-Amino-1MQ are limited, as research to date has been largely preclinical. Adverse events are not summarized in the cited animal studies, and no controlled human trials establishing a safety profile have been identified. Because of this, conclusions about tolerability, interactions or long-term effects cannot be drawn. The compound is supplied strictly for laboratory research use and is not approved for any medical indication.

Research protocols have used 2.5 to 5 mg per administration, once daily in the morning, via the subcutaneous route, run in 8-week blocks followed by 4 weeks off. These figures describe amounts reported in research protocols and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. Given the preclinical status of this compound, such protocols have not been validated in controlled human studies.